Johnson & Johnson Cost of Revenue
Johnson & Johnson (JNJ) reported Cost of Revenue of $8.05 billion for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-23
- Johnson & Johnson cost of goods and services sold for the quarter ending 2026-06-28 was $8.05B, a 5.55% increase year-over-year.
- Johnson & Johnson cost of goods and services sold for the quarter ending 2026-03-29 was $8.11B, a 10.18% increase year-over-year.
- Johnson & Johnson cost of goods and services sold for the quarter ending 2025-12-28 was $7.97B, a 11.78% increase year-over-year.
- Johnson & Johnson cost of goods and services sold for the quarter ending 2025-09-28 was $7.30B, a 4.88% increase year-over-year.
- Johnson & Johnson cost of goods and services sold for fiscal 2025 was $30.26B, a 10.14% increase from fiscal 2024.
- Johnson & Johnson cost of goods and services sold for fiscal 2024 was $27.47B, a 3.46% increase from fiscal 2023.
- Johnson & Johnson cost of goods and services sold for fiscal 2023 was $26.55B, a 7.96% increase from fiscal 2023.
- Johnson & Johnson cost of goods and services sold for fiscal 2023 was $24.60B, a 5.10% increase from fiscal 2022.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | $8.05B 10-Q · filed 2026-07-23 | $16.16B 10-Q · filed 2026-07-23 | $24.13B derived: sum of 3 quarters · filed 2026-07-23 | $31.43B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2026-03-29 | $8.11B 10-Q · filed 2026-04-22 | $16.07B derived: sum of 2 quarters · filed 2026-04-22 | $23.38B derived: sum of 3 quarters · filed 2026-04-22 | $31.00B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-12-28 | $7.97B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $15.27B derived: sum of 2 quarters · filed 2026-02-11 | $22.90B derived: sum of 3 quarters · filed 2026-07-23 | $30.26B 10-K · filed 2026-02-11 | ||||
| 2025-09-28 | $7.30B 10-Q · filed 2025-10-22 | $14.93B derived: sum of 2 quarters · filed 2026-07-23 | $22.29B 10-Q · filed 2025-10-22 | $29.42B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-06-29 | $7.63B 10-Q · filed 2026-07-23 | $14.98B 10-Q · filed 2026-07-23 | $22.11B derived: sum of 3 quarters · filed 2026-07-23 | $29.08B derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-03-30 | $7.36B 10-Q · filed 2026-04-22 | $14.48B derived: sum of 2 quarters · filed 2026-04-22 | $21.45B derived: sum of 3 quarters · filed 2026-04-22 | $28.32B derived: sum of 4 quarters · filed 2026-04-22 | ||||
| 2024-12-29 | $7.13B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $14.09B derived: sum of 2 quarters · filed 2026-02-11 | $20.96B derived: sum of 3 quarters · filed 2026-02-11 | $27.47B 10-K · filed 2026-02-11 | ||||
| 2024-09-29 | $6.96B 10-Q · filed 2025-10-22 | $13.83B derived: sum of 2 quarters · filed 2025-10-22 | $20.34B 10-Q · filed 2025-10-22 | $27.14B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $6.87B 10-Q · filed 2025-07-24 | $13.38B 10-Q · filed 2025-07-24 | $20.18B derived: sum of 3 quarters · filed 2026-02-11 | $26.78B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $6.51B 10-Q · filed 2025-04-23 | $13.31B derived: sum of 2 quarters · filed 2026-02-11 | $19.91B derived: sum of 3 quarters · filed 2026-02-11 | $26.38B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $6.80B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $13.40B derived: sum of 2 quarters · filed 2026-02-11 | $19.87B derived: sum of 3 quarters · filed 2026-02-11 | $26.55B 10-K · filed 2026-02-11 | ||||
| 2023-10-01 | $6.61B 10-Q · filed 2024-10-23 | $13.07B derived: sum of 2 quarters · filed 2024-10-23 | $19.75B 10-Q · filed 2024-10-23 | $25.84B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-07-02 | $6.46B 10-Q · filed 2024-07-25 | $8.21B 10-Q · filed 2023-07-31 | $13.15B 10-Q · filed 2024-07-25 | $16.61B 10-Q · filed 2023-07-31 | $19.23B derived: sum of 3 quarters · filed 2025-02-13 | $25.41B derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-04-02 | $6.69B 10-Q · filed 2024-05-01 | $8.39B 10-Q · filed 2023-04-28 | $12.77B derived: sum of 2 quarters · filed 2025-02-13 | $18.94B derived: sum of 3 quarters · filed 2025-02-13 | $26.86B derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-01-01 | $6.08B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $12.26B derived: sum of 2 quarters · filed 2025-02-13 | $20.18B derived: sum of 3 quarters · filed 2025-02-13 | $24.60B 10-K · filed 2025-02-13 | $31.09B 10-K · filed 2023-02-16 | |||
| 2022-10-02 | $6.17B 10-Q · filed 2023-10-27 | $7.81B 10-Q · filed 2022-10-27 | $14.09B derived: sum of 2 quarters · filed 2023-10-27 | $18.51B 10-Q · filed 2023-10-27 | $23.32B 10-Q · filed 2022-10-27 | $23.19B derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-07-03 | $7.92B 10-Q · filed 2023-07-31 | $15.52B 10-Q · filed 2023-07-31 | $17.02B derived: sum of 3 quarters · filed 2024-02-16 | $24.27B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-04-03 | $7.60B 10-Q · filed 2023-04-28 | $9.10B derived: sum of 2 quarters · filed 2024-02-16 | $16.35B derived: sum of 3 quarters · filed 2024-02-16 | $23.94B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-01-02 | $1.50B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $8.75B derived: sum of 2 quarters · filed 2024-02-16 | $16.34B derived: sum of 3 quarters · filed 2024-02-16 | $23.40B 10-K · filed 2024-02-16 | $29.86B 10-K · filed 2022-02-17 | |||
| 2021-10-03 | $7.25B 10-Q · filed 2022-10-27 | $14.84B derived: sum of 2 quarters · filed 2022-10-27 | $21.90B 10-Q · filed 2022-10-27 | $29.71B derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-07-04 | $7.59B 10-Q · filed 2022-07-29 | $14.65B 10-Q · filed 2022-07-29 | $22.46B derived: sum of 3 quarters · filed 2023-02-16 | $29.44B derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-04-04 | $7.06B 10-Q · filed 2022-04-29 | $14.88B derived: sum of 2 quarters · filed 2023-02-16 | $21.85B derived: sum of 3 quarters · filed 2023-02-16 | $28.43B derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-01-03 | $7.81B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $14.79B derived: sum of 2 quarters · filed 2023-02-16 | $21.36B derived: sum of 3 quarters · filed 2023-02-16 | $28.43B 10-K · filed 2023-02-16 | ||||
| 2020-09-27 | $6.97B 10-Q · filed 2021-10-29 | $13.55B derived: sum of 2 quarters · filed 2021-10-29 | $20.61B 10-Q · filed 2021-10-29 | $27.75B derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-06-28 | $6.58B 10-Q · filed 2021-07-29 | $13.64B 10-Q · filed 2021-07-29 | $20.77B derived: sum of 3 quarters · filed 2022-02-17 | $27.64B derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-03-29 | $7.06B 10-Q · filed 2021-04-30 | $14.20B derived: sum of 2 quarters · filed 2022-02-17 | $21.06B derived: sum of 3 quarters · filed 2022-02-17 | $28.00B derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2019-12-29 | $7.13B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $14.00B derived: sum of 2 quarters · filed 2022-02-17 | $20.94B derived: sum of 3 quarters · filed 2022-02-17 | $27.56B 10-K · filed 2022-02-17 | ||||
| 2019-09-29 | $6.87B 10-Q · filed 2020-10-23 | $13.81B derived: sum of 2 quarters · filed 2020-10-23 | $20.42B 10-Q · filed 2020-10-23 | $27.38B derived: sum of 4 quarters · filed 2021-02-22 | ||||
| 2019-06-30 | $6.94B 10-Q · filed 2020-07-24 | $13.55B 10-Q · filed 2020-07-24 | $20.52B derived: sum of 3 quarters · filed 2021-02-22 | $27.11B derived: sum of 4 quarters · filed 2021-02-22 | ||||
| 2019-03-31 | $6.62B 10-Q · filed 2020-04-29 | $13.58B derived: sum of 2 quarters · filed 2021-02-22 | $20.16B derived: sum of 3 quarters · filed 2021-02-22 | $27.09B derived: sum of 4 quarters · filed 2021-02-22 | ||||
| 2018-12-30 | $6.96B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-22 | $13.55B derived: sum of 2 quarters · filed 2021-02-22 | $20.48B derived: sum of 3 quarters · filed 2021-02-22 | $27.09B 10-K · filed 2021-02-22 | ||||
| 2018-09-30 | $6.59B 10-Q · filed 2019-10-28 | $13.52B derived: sum of 2 quarters · filed 2019-10-28 | $20.13B 10-Q · filed 2019-10-28 | $27.39B derived: sum of 4 quarters · filed 2020-02-18 | ||||
| 2018-07-01 | $6.93B 10-Q · filed 2019-07-29 | $13.54B 10-Q · filed 2019-07-29 | $20.80B derived: sum of 3 quarters · filed 2020-02-18 | $27.73B derived: sum of 4 quarters · filed 2020-02-18 | ||||
| 2018-04-01 | $6.61B 10-Q · filed 2019-05-01 | $13.87B derived: sum of 2 quarters · filed 2020-02-18 | $20.80B derived: sum of 3 quarters · filed 2020-02-18 | |||||
| 2017-12-31 | $7.26B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-18 | $14.18B derived: sum of 2 quarters · filed 2020-02-18 | $25.44B 10-K · filed 2020-02-18 | |||||
| 2017-10-01 | $6.92B 10-Q · filed 2018-10-31 | $18.18B 10-Q · filed 2018-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |